Literature DB >> 22993639

Increased expression but not sensitivity to Fas/CD95 in glioblastoma cells depleted of mitochondrial DNA.

Bertrand C Liang1.   

Abstract

Mitochondria and Fas (CD95) play a role in tumorigenicity and apoptosis. In the present study, the functional relationship of mitochondria to Fas in mediating apoptosis was investigated. Glioblastoma cells (DBTRGO5MG, U87) were depleted of mitochondrial DNA (mtDNA) by treatment with ethidium bromide (Rho(-) cells). Compared to Rho(+) cells, Rho(-) cells showed enhanced expression of Fas at the cell surface. Indeed, when Rho(+) cells were treated with mitochondrial respiratory chain complex inhibitors, Fas cell surface expression was noted to increase in a similar fashion to the depletion of mtDNA in both cell lines. However, when cells were evaluated for sensitivity to apoptosis using Fas-engagement, there was no difference between the Rho(+) and Rho(-) cells in either cell line. By contrast, sensitivity to the cytotoxic agent cis-diammine-dichloroplatinum (cisplatin) was markedly increased in the Rho(-) cells, which expressed higher levels of cell surface Fas. Expression of Fas is increased with the depletion of mtDNA and respiratory complex inhibitors. However, this increase in expression does not necessarily translate to an increase in sensitivity to Fas-engagement, although there is an increase in the sensitivity of depleted cells to cytotoxic agents such as cisplatin.

Entities:  

Year:  2010        PMID: 22993639      PMCID: PMC3445987          DOI: 10.3892/etm.2010.158

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  71 in total

1.  Fas-mediated apoptosis in human prostatic carcinoma cell lines.

Authors:  O W Rokhlin; G A Bishop; B S Hostager; T J Waldschmidt; S P Sidorenko; N Pavloff; M C Kiefer; S R Umansky; R A Glover; M B Cohen
Journal:  Cancer Res       Date:  1997-05-01       Impact factor: 12.701

2.  Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness.

Authors:  L B Owen-Schaub; R Radinsky; E Kruzel; K Berry; S Yonehara
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

3.  Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization.

Authors:  E Bossy-Wetzel; D D Newmeyer; D R Green
Journal:  EMBO J       Date:  1998-01-02       Impact factor: 11.598

Review 4.  The proto-oncogene Bcl-2 and its role in regulating apoptosis.

Authors:  G Kroemer
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

5.  Inhibition of death receptor signals by cellular FLIP.

Authors:  M Irmler; M Thome; M Hahne; P Schneider; K Hofmann; V Steiner; J L Bodmer; M Schröter; K Burns; C Mattmann; D Rimoldi; L E French; J Tschopp
Journal:  Nature       Date:  1997-07-10       Impact factor: 49.962

6.  Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.

Authors:  A Villunger; A Egle; M Kos; B L Hartmann; S Geley; R Kofler; R Greil
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

7.  Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines.

Authors:  J J Westendorf; J M Lammert; D F Jelinek
Journal:  Blood       Date:  1995-06-15       Impact factor: 22.113

8.  Fas antigen and p55 TNF receptor signal apoptosis through distinct pathways.

Authors:  G H Wong; D V Goeddel
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

9.  Bcl-2 inhibits the mitochondrial release of an apoptogenic protease.

Authors:  S A Susin; N Zamzami; M Castedo; T Hirsch; P Marchetti; A Macho; E Daugas; M Geuskens; G Kroemer
Journal:  J Exp Med       Date:  1996-10-01       Impact factor: 14.307

10.  Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death.

Authors:  N Zamzami; P Marchetti; M Castedo; D Decaudin; A Macho; T Hirsch; S A Susin; P X Petit; B Mignotte; G Kroemer
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.